Judah Folkman just told Reuter that TAP=-=a joint venture between Abbott and Takeda has a potential drug candidate which works on mice. This is the continuation of Angiogenesis story. This may head to phase I trial later this year or next year. For those of you who do not know about TAP, it is a joint venture between Japan's Takeda Pharmaceutical and Abbott. Abbott international funds the research in the joint venture and derives profit from the prodcut produced by TAP. TAP pretty much behaves like an independent entity, it is fairly tricky to account the contribution of TAP profit to Abbott's profit. Anyway, thought your guys would like to know. I stand partially corrected on the assertion that Abbott does not have a cancer drug candidate, however, Abbott itself still does not have a cancer drug candidate. Recently Abbott also has closed the antifungal program as well as a cancer research program. Hope the stock will go up a little on Monday on the news.